Stopped Early

AstraZeneca deal halts investigator-led ESO-T01 CAR-T trial for myeloma in China

Union Hospital suspended its Early Phase 1 trial of the in vivo BCMA CAR-T candidate ESO-T01 after AstraZeneca acquired its developer, EsoBiotec.

Union Hospital's investigator-initiated trial of ESO-T01, an in vivo BCMA CAR-T candidate, moved from Recruiting to Suspended after AstraZeneca acquired the therapy's developer, EsoBiotec.

By AppliedXLJuly 22, 2026Trial NCT06691685

Executive Summary

An investigator-run Early Phase 1 trial testing an in vivo-generated BCMA CAR-T therapy in relapsed or refractory multiple myeloma was suspended after the drug's developer was acquired by a larger pharmaceutical company, not because of a safety or efficacy problem.
The therapy was designed to reprogram T cells inside the body rather than manufacturing CAR-T cells outside it, a distinct approach within a BCMA field otherwise dominated by ex vivo cell therapies and bispecific antibodies already approved for this disease.
The BCMA target in multiple myeloma is already validated by multiple approved therapies, so a pause in this small academic trial removes one exploratory entrant rather than a proven treatment option from a landscape that remains active.
The acquiring company's plans for the underlying technology, not the trial's own data, will determine whether this specific study resumes.

The suspension

The trial, registered as NCT06691685, changed status from Recruiting to Suspended on July 22, 2026, with the registry citing the reason directly: "The collaborator EsoBiotec was acquired by AstraZeneca". The study had been recruiting since January 2025 toward a target enrollment of 24 adults with BCMA-positive multiple myeloma who had received at least two prior lines of therapy. Its primary completion date remains listed as November 1, 2027, and enrollment held flat at its 24-patient target through the suspension, a change the operational model treats as routine for an Early Phase 1 study. NCT06691685

Probability of Success

Endpoint Met20%

Completes70%

Clinical Significance9%

Regulatory36%

What the trial tested

ESO-T01 is designed to generate CAR-T cells inside the patient's body rather than through an external manufacturing process, and does not require lymphodepleting chemotherapy before treatment, according to the developer's own announcement when the trial dosed its first patient. That release also reported no cancer cells detected in bone marrow 28 days after dosing and described the collaboration between EsoBiotec and Shenzhen Pregene Biopharma that produced the candidate. The trial's primary endpoints are safety measures: cytokine release syndrome, dose-limiting toxicities, treatment-related adverse events, and neurotoxicity (ICANS), assessed through 28 days post-infusion and, for adverse events broadly, through two years. Secondary endpoints track CAR-T cell expansion kinetics, response rate, duration of response, progression-free survival and overall survival. A+1

The competitive field

BCMA is an established target in multiple myeloma, with six approved therapies against it including Janssen's ciltacabtagene autoleucel and Celgene's idecabtagene vicleucel, both CAR-T therapies, alongside bispecific antibodies from Pfizer, Regeneron and GlaxoSmithKline. Fifteen direct comparators are active in Phase 1 through Phase 4, including newer BCMA bispecifics from AbbVie and Janssen and additional BCMA CAR-T programs from Nanjing IASO Biotechnology and Alexion Pharmaceuticals. Within that crowded, already-validated field, ESO-T01's in vivo generation approach and lack of a lymphodepletion requirement set it apart from the ex vivo-manufactured CAR-T products on the market, a design intended to simplify delivery and shorten time to treatment, though the trial's suspension means that hypothesis remains untested here.

The sponsor and the asset

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, the trial's academic sponsor, has completed all three of its previously tracked trials with no terminations on record. A second, separately registered investigator trial of ESO-T01 at the same indication, NCT06791681, remains listed as Recruiting, indicating the drug program itself continues in at least one active site even as this trial pauses. Early Phase 1 trials in this specific target-and-indication combination have a mixed history: of three prior trials at this phase for BCMA in multiple myeloma, one completed and two terminated. NCT06691685

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.